We are live on
!
Find out more
CNCR
ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR
Delisted
CNCR was delisted on the 27th of May, 2025.
14 hedge funds and large institutions have $2.15M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
less ownership
Funds ownership: →
74% less capital invested
Capital invested by funds: $8.44M → $2.15M (-$6.29M)
Holders
14
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$323K | |
| 2 | +$248K | |
| 3 | +$176K | |
| 4 |
Vontobel Holding
Zurich,
Switzerland
|
+$120K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$16.8K |
Top Sellers
| 1 | -$6.92M | |
| 2 | -$312K | |
| 3 | -$21.2K | |
| 4 |
Morgan Stanley
New York
|
-$6.88K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$3.93K |